Best Hair Loss Treatment in Milton Keynes—SVR Aesthetics

HAIR LOSS TREATMENT

Hair loss is one of the problems that is found common in both men and women, so SVR Aesthetic is giving you one of the best hair loss treatment for females in the Milton Keynes part of England, UK. So you may want to know what the best treatment for hair loss is? Book your appointment now. Get a free consultation just to know which hair loss treatment is best for you. which gives exactly the look that you are looking for. So here you go; we offer the best hair treatment for hair loss​.

 

 

BEST HAIR lOSS TREATMENT IN MILTON KEYNES 2025

If you’re looking for the best hair loss treatment for female UK​ and the best men’s hair loss treatment,​ then you have come to the right place.

What is the Best Hair Loss Treatment?

Milton Keynes is considered one of the top places in the UK because it has SVR Aesthetics, which offers the best hair loss treatment of your life. But first, we have to know what causes your hair loss problem. Doctor will call you for the physical examination just to know if it is genetics, hair care routine, an unhealthy diet, or stress. We have to measure all the problems before giving you the solutions, and after that, we will offer you the top-grade hair loss treatment for females and males in the UK. You have to give blood, test, do light microscopy, do a scalp biopsy, and do a pull test.

MEDICATIONS

Minoxidil (Rogaine)

Minoxidil (Rogaine) is the best hair regrowth treatmentandthe best medication for hair losswhich gives results in 6 months. What you have to do is apply it to the scalp once a day for women and twice for men because it’s in a liquid shampoo form. It will slow down the rate of hair loss.

Finasteride (Propecia)

Finasteride (Propecia) is the best hair treatment for baldness, but ​it is only for men, and also men aged 60 are not recommended to take it. Used for the same purpose, like for the regrowth and slowing down of the hair loss. But it has cons; on the other hand, it can cause an increased risk of prostate cancer.